doi: 10.1038/s41419-022-04775-z 89 AgoroRTalebMQuesniauxVFJMuraC
Moreover, investigations within a porcine myocardial infarction model have shown that MCC950 notably diminishes infarct size and alleviates cardiomyocyte pyroptosis through the inhibition of NLRP3 inflammasome activation, consequently reducing the release of inflammatory factors (IL1, IL18)
Protocol Overview At 500 mcg/mL a single 1 mg vial holds 2 mL of usable solution twenty 100 mcg-equivalents, or (at a typical 30 mcg daily dose) roughly a month of research use from one vial
10.1186/s12872-024-04236-939438792 200 Zhu S, Zhang M, Cheng S, et al
PMID: 21593563 [vi] Park SA, Byeon G, Jhoo JH, Kim HC, Lim MN, Jang JW, Bae JB, Han JW, Kim TH, Kwak KP, Kim BJ, Kim SG, Kim JL, Moon SW, Park JH, Ryu SH, Youn JC, Lee DW, Lee SB, Lee JJ, Lee DY, Kim KW
The infusion rate is initially slow and then gradually increased if no adverse reactions occur